Psychiatrists often stick with the same medications for serious mental illnesses like schizophrenia and bipolar disorder, even when patients aren't improving, according to a new analysis of a phenomenon called therapeutic inertia. This tendency to avoid making changes affects treatment outcomes and leaves many people with severe mental illness struggling unnecessarily.

What Is Therapeutic Inertia in Mental Health?

Therapeutic inertia is the clinical tendency to continue with an existing treatment plan without modification, despite evidence that a patient isn't responding well. In psychiatry, this means a person might stay on an antipsychotic medication that isn't controlling their psychotic symptoms, or remain on a mood stabilizer that leaves them cycling between depressive and manic episodes. The problem isn't unique to psychiatry; it occurs across medicine, from diabetes care to blood pressure management. But in mental health, the stakes feel particularly high because untreated psychosis and mood instability can derail a person's entire life.

A comprehensive framework published in July 2026 examined why this happens and identified multiple layers of barriers that keep psychiatrists from making necessary medication changes. The research shows that therapeutic inertia isn't simply about clinician laziness or indifference; it's a complex problem rooted in uncertainty, organizational constraints, and the inherent difficulty of psychiatric decision-making.

Why Do Psychiatrists Hesitate to Change Medications?

The reasons psychiatrists avoid adjusting treatment are surprisingly varied. At the individual clinician level, uncertainty plays a major role. Psychiatry deals with subjective symptoms that can't be measured with a blood test. When a patient says they're still hearing voices or feeling depressed, the clinician must decide whether to switch medications, increase the dose, add another drug, or wait longer for the current treatment to work. That ambiguity creates psychological discomfort, and sometimes doing nothing feels safer than making a change that could backfire.

Organizational and structural factors also matter enormously. Many psychiatric practices lack the time, resources, or multidisciplinary support needed to carefully review and adjust treatment plans. When a psychiatrist is seeing 30 patients a day, spending 20 minutes on a complex medication review becomes a luxury. Additionally, shared decision-making with patients, which research shows improves outcomes, requires conversation and collaboration that busy clinics often can't accommodate.

How Does Therapeutic Inertia Affect Specific Conditions?

The problem is especially pronounced in schizophrenia spectrum disorders, where therapeutic inertia directly impacts the use of clozapine. Clozapine is one of the most effective antipsychotics available, particularly for treatment-resistant schizophrenia, yet many patients who could benefit from it never receive it because psychiatrists hesitate to initiate or switch to this medication. The barriers include concerns about side effects, the need for regular blood monitoring, and uncertainty about whether a patient has truly failed adequate trials of other antipsychotics.

The framework identifies several key factors that drive therapeutic inertia across psychiatric disorders:

• Clinical Uncertainty: Psychiatrists struggle with ambiguous symptom presentations and subjective outcome measures, making it difficult to know when a medication truly isn't working versus when more time is needed.
• Risk Perception: Clinicians may overestimate the risks of switching medications while underestimating the risks of leaving a patient untreated or inadequately treated.
• Organizational Barriers: Limited appointment time, lack of multidisciplinary teams, and insufficient decision support systems make it harder to implement medication changes systematically.
• Patient and Family Factors: Patients may resist medication changes due to side effects, stigma, or previous negative experiences, and clinicians may avoid conflict by maintaining the status quo.

What Solutions Are Experts Proposing?

The research framework suggests several evidence-based strategies to overcome therapeutic inertia. Shared decision-making, where clinicians and patients collaborate on treatment choices, has strong evidence for improving outcomes. Multidisciplinary reviews, where psychiatrists discuss complex cases with pharmacists, nurses, and other specialists, can reduce uncertainty and catch cases where medication changes are overdue. Professional education that helps clinicians recognize and acknowledge their own therapeutic inertia is also important.

Emerging technologies offer additional promise. Artificial intelligence and precision psychiatry tools could help clinicians identify which patients are likely to respond to specific medications, reducing the guesswork. Real-world evidence from electronic health records can show clinicians how similar patients fared when their medications were adjusted, providing concrete data rather than abstract uncertainty.

How to Improve Treatment Outcomes for Serious Mental Illness

• Seek Shared Decision-Making: If you or a loved one has schizophrenia, bipolar disorder, or another serious mental illness, ask your psychiatrist to discuss treatment options collaboratively, including the pros and cons of medication changes.
• Request Multidisciplinary Review: If you've been on the same medication for months without improvement, ask whether your case can be reviewed by a team that includes a pharmacist or other specialists who might spot new options.
• Track Symptoms Systematically: Keep a simple log of key symptoms, side effects, and how you're functioning. Objective data can help your psychiatrist recognize when a medication truly isn't working.
• Discuss Clozapine Explicitly: If you have treatment-resistant schizophrenia, specifically ask your psychiatrist whether clozapine has been adequately considered, since therapeutic inertia often delays access to this highly effective medication.

The Bigger Picture: Breaking the Cycle

Therapeutic inertia represents a gap between what research shows works and what actually happens in clinical practice. People with schizophrenia spectrum disorders die one to two decades earlier than the general population, and much of that mortality gap is driven by preventable physical health conditions that could be better managed with optimized psychiatric treatment. When therapeutic inertia keeps someone on an inadequate antipsychotic dose or delays a switch to a more effective medication, it perpetuates suffering and worsens long-term outcomes.

The framework published in 2026 doesn't offer a single fix, but rather a roadmap for recognizing therapeutic inertia at multiple levels: the individual clinician, the patient-clinician relationship, the clinic or hospital system, and the broader healthcare environment. Addressing it will require changes in how psychiatrists are trained, how clinics are organized, and how patients are empowered to advocate for themselves.

For now, the most practical step is awareness. If you've been on the same psychiatric medication for a long time without significant improvement, it's reasonable to ask your psychiatrist directly: "Is this medication working as well as it could? Have we considered other options?" That conversation might be the first step toward breaking through therapeutic inertia and finding a treatment that actually helps.